Literature DB >> 8971306

Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori.

L Laine1, R Estrada, M Trujillo, K Fukanaga, G Neil.   

Abstract

BACKGROUND: We assessed the efficacy, compliance, and tolerability of the twice-a-day triple therapy, amoxycillin, omeprazole, and clarithromycin, for Helicobacter pylori and studied the effect of treatment duration (7, 10 or 14 days) on these factors.
METHODS: One-hundred and fifty subjects with H. pylori infection documented by 13C-urea breath test were randomly assigned to a 7, 10 or 14-day course of amoxycillin 1 g b.d., omeprazole 20 mg b.d. and clarithromycin 500 mg b.d. Subjects returned at the end of therapy for pill count and assessment of side-effects. Subjects returned for a repeat 13C-urea breath test 4 weeks after the end of therapy.
RESULTS: Poor compliance (< 80% of medications taken) was seen in 0 subjects at 7 days, 6% at 10 days, and 10% at 14 days (P = 0.03 by chi 2 test for trend; difference for 7 vs. 14 days = 10%; 95% CI, -2% to 18%; P = 0.056). Intention-to-treat eradication rates were 86% at 7 days, 90% at 10 days and 92% at 14 days. Per-protocol eradication rates were 86% at 7 days, 91% at 10 days, and 95% at 14 days (P = 0.11; difference for 7 vs. 14 days = 9%; 95% CI, -2% to 21%; P = 0.17).
CONCLUSIONS: One week of twice-a-day amoxycillin, omeprazole and clarithromycin is well tolerated and provides a good rate of H. pylori eradication. Increasing the duration of therapy decreases compliance but has the potential to modestly improve efficacy if the patient takes the full complement of medication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971306     DOI: 10.1046/j.1365-2036.1996.111282000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection.

Authors:  Ala I Sharara; Fayez S Sarkis; Mustapha M El-Halabi; Ahmad Malli; Nabil M Mansour; Cecilio Azar; Mohamad A Eloubeidi; Fadi H Mourad; Kassem Barada; Ismail Sukkarieh
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

2.  Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.

Authors:  D J Kearney; A Brousal
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

3.  Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity?

Authors:  Carlos Robles-Jara; Carlos Robles-Medranda; Manuel Moncayo; Byron Landivar; Johnny Parrales
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 4.  Treatment after failure: the problem of "non-responders".

Authors:  J Q Huang; R H Hunt
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

5.  Helicobacter pylori-induced gastritis may contribute to occurrence of postprandial symptomatic hypoglycemia.

Authors:  O Açbay; A F Celik; P Kadioğlu; S Göksel; S Gündoğdu
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

6.  Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans.

Authors:  Seiji Shiota; Rita Reddy; Abeer Alsarraj; Hashem B El-Serag; David Y Graham
Journal:  Clin Gastroenterol Hepatol       Date:  2015-02-11       Impact factor: 11.382

7.  Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.

Authors:  Rocco Maurizio Zagari; Gabriele Bianchi-Porro; Roberto Fiocca; Giovanni Gasbarrini; Enrico Roda; Franco Bazzoli
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

Review 8.  Cultural relevance in medication adherence interventions with underrepresented adults: systematic review and meta-analysis of outcomes.

Authors:  Vicki S Conn; Maithe Enriquez; Todd M Ruppar; Keith C Chan
Journal:  Prev Med       Date:  2014-10-28       Impact factor: 4.018

Review 9.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 10.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.